Despite tremendous slowdown of most business and economic activities, drug companies, pharmaceutical behemoths are vouching tangible economic activities as search for a suitable vaccine to combat novel corona virus is still on.
One of the most prominent drug maker ahead in the race is Europe's AstraZeneca which is currently bagged substantial regulatory compliance and nod for twin probable drugs for critical ailments such as cancer and the much anticipated corona vaccine. The former is directed towards treating the condition of cancer with the drug, Lynparza. The development is rife for pipeline expansion of AstraZeneca.
Lynparza has bagged substantial recommendation for adoption in the treatment of pancreatic cancer and the drug has also received a green signal from European health regulatory body. Yet another drug, Brilinta has also received recommendation as a cardiac drug. These developments have cemented AstraZeneca's position as one of the most promising drug making company in London.
To add to its list of recent milestones, AstraZeneca is also touted to have received substantial funding from the US government to make crucial advances in coining its flagship vaccine for the deadly corona virus that has claimed millions of lives globally. The development is likely to make legit advances in offering a billion of coronavirus drug doses later this year as well as early next year.
The company has also settled for workforce expansion with the most recent hiring of French pharmacist, Roch Doliveux as chairman of the gene and cell therapy wing of the company, considering the undeniable role of vaccination in curing corona virus.
In this light, AstraZeneca has also inked a partnership deal with Oxford Biomedica just last week to offer several batches of this coveted vaccine which is currently undergoing human testing. The contract is signed for a year tenure. The company is also known for its high end drugs catering to cardiac and cancer ailments.